Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    5,013.17
    -58.46 (-1.15%)
     
  • Dow

    37,834.47
    -626.45 (-1.63%)
     
  • Nasdaq

    15,496.56
    -216.18 (-1.38%)
     
  • Bitcoin USD

    63,641.85
    -1,801.89 (-2.75%)
     
  • CMC Crypto 200

    1,378.46
    -4.11 (-0.30%)
     
  • FTSE 100

    8,054.18
    +13.80 (+0.17%)
     
  • Gold

    2,335.70
    -2.70 (-0.12%)
     
  • Crude Oil

    82.03
    -0.78 (-0.94%)
     
  • 10-Yr Bond

    4.7190
    +0.0670 (+1.44%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Surge in patients increases Raffles Medical’s 3Q14 revenue by 11.1%

As healthcare insurance services also spike.

4Q is traditionally Raffles Medical Group’s strongest quarter, but this time 3Q is also bringing in solid statistics.

According to a report by OCBC Investment Research, Raffles Medical Group (RMG) reported a double-digit YoY growth in both its topline and bottomline for its 3Q14 results.

Revenue was up 11.1% YoY to S$94.5m due to a higher patient load, addition of specialist consultants and increased provision of healthcare insurance services; while PATMI jumped by 11.3% to S$15.4m.

For 9M14, revenue increased 8.6% to S$274.6m, and constituted 72.1% of our FY14 forecast. PATMI rose 9.2% to S$45.6m, or 67.1% of OCBC’s full-year projection.

ADVERTISEMENT



More From Singapore Business Review